BIOMAT Database Logo BIOMAT Database Logo

Structure-based design of inhibitors of purine nucleoside phosphorylase. 2. 9-Alicyclic and 9-heteroalicyclic derivatives of 9-deazaguanine. 1993

J A Secrist, and S Niwas, and J D Rose, and Y S Babu, and C E Bugg, and M D Erion, and W C Guida, and S E Ealick, and J A Montgomery
BioCryst Pharmaceuticals, Inc., Birmingham, Alabama 35244.

Alicyclic and heteroalicyclic derivatives of 9-deazaguanine (2-amino-1,5-dihydro-4H-pyrrolo[3,2-d] [pyrimidin-4-one) are, with one exception, potent inhibitors of purine nucleoside phosphorylase (PNP) equaling the corresponding 9-arylmethyl derivatives previously investigated. The mode of binding of these compounds to PNP was determined by X-ray crystallography.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D009010 Monte Carlo Method In statistics, a technique for numerically approximating the solution of a mathematical problem by studying the distribution of some random variable, often generated by a computer. The name alludes to the randomness characteristic of the games of chance played at the gambling casinos in Monte Carlo. (From Random House Unabridged Dictionary, 2d ed, 1993) Method, Monte Carlo
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011683 Purine-Nucleoside Phosphorylase An enzyme that catalyzes the reaction between a purine nucleoside and orthophosphate to form a free purine plus ribose-5-phosphate. EC 2.4.2.1. Inosine Phosphorylase,Nicotinamide Riboside Phosphorylase,Purine Nucleoside Phosphorylases,Nucleoside Phosphorylases, Purine,Phosphorylase, Inosine,Phosphorylase, Nicotinamide Riboside,Phosphorylase, Purine-Nucleoside,Phosphorylases, Purine Nucleoside,Purine Nucleoside Phosphorylase,Riboside Phosphorylase, Nicotinamide
D003516 Cycloparaffins Alicyclic hydrocarbons in which three or more of the carbon atoms in each molecule are united in a ring structure and each of the ring carbon atoms is joined to two hydrogen atoms or alkyl groups. The simplest members are cyclopropane (C3H6), cyclobutane (C4H8), cyclohexane (C6H12), and derivatives of these such as methylcyclohexane (C6H11CH3). (From Sax, et al., Hawley's Condensed Chemical Dictionary, 11th ed) Cyclic Olefins,Cycloalkanes,Cycloalkenes,Cycloalkynes,Cyclic Acetylenes,Cyclic Alkenes,Alkenes, Cyclic,Olefins, Cyclic
D006147 Guanine
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013816 Thermodynamics A rigorously mathematical analysis of energy relationships (heat, work, temperature, and equilibrium). It describes systems whose states are determined by thermal parameters, such as temperature, in addition to mechanical and electromagnetic parameters. (From Hawley's Condensed Chemical Dictionary, 12th ed) Thermodynamic

Related Publications

J A Secrist, and S Niwas, and J D Rose, and Y S Babu, and C E Bugg, and M D Erion, and W C Guida, and S E Ealick, and J A Montgomery
Structure-based design of inhibitors of purine nucleoside phosphorylase. 5. 9-Deazahypoxanthines.
July 1994, Journal of medicinal chemistry,
J A Secrist, and S Niwas, and J D Rose, and Y S Babu, and C E Bugg, and M D Erion, and W C Guida, and S E Ealick, and J A Montgomery
Structure-based design of inhibitors of purine nucleoside phosphorylase.
July 1995, Acta crystallographica. Section D, Biological crystallography,
J A Secrist, and S Niwas, and J D Rose, and Y S Babu, and C E Bugg, and M D Erion, and W C Guida, and S E Ealick, and J A Montgomery
Structure-based drug design: inhibitors of purine nucleoside phosphorylase.
February 1993, Farmaco (Societa chimica italiana : 1989),
J A Secrist, and S Niwas, and J D Rose, and Y S Babu, and C E Bugg, and M D Erion, and W C Guida, and S E Ealick, and J A Montgomery
Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds.
August 1993, The Journal of pharmacology and experimental therapeutics,
J A Secrist, and S Niwas, and J D Rose, and Y S Babu, and C E Bugg, and M D Erion, and W C Guida, and S E Ealick, and J A Montgomery
Structure-based drug design: inhibitors of purine nucleoside phosphorylase. Index: structure-based drug design: inhibitors of PNP.
June 1994, Drug design and discovery,
J A Secrist, and S Niwas, and J D Rose, and Y S Babu, and C E Bugg, and M D Erion, and W C Guida, and S E Ealick, and J A Montgomery
Design of purine nucleoside phosphorylase inhibitors.
November 1986, Federation proceedings,
J A Secrist, and S Niwas, and J D Rose, and Y S Babu, and C E Bugg, and M D Erion, and W C Guida, and S E Ealick, and J A Montgomery
9-Deazaguanine derivatives connected by a linker to difluoromethylene phosphonic acid are slow-binding picomolar inhibitors of trimeric purine nucleoside phosphorylase.
April 2010, The FEBS journal,
J A Secrist, and S Niwas, and J D Rose, and Y S Babu, and C E Bugg, and M D Erion, and W C Guida, and S E Ealick, and J A Montgomery
The biochemical and pharmacological activity of 9-benzyl-9-deazaguanine, a potent purine nucleoside phosphorylase (PNP) inhibitor.
August 1995, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
J A Secrist, and S Niwas, and J D Rose, and Y S Babu, and C E Bugg, and M D Erion, and W C Guida, and S E Ealick, and J A Montgomery
Fluorescence studies of calf spleen purine nucleoside phosphorylase (PNP) complexes with guanine and 9-deazaguanine.
January 2007, Nucleosides, nucleotides & nucleic acids,
J A Secrist, and S Niwas, and J D Rose, and Y S Babu, and C E Bugg, and M D Erion, and W C Guida, and S E Ealick, and J A Montgomery
Structure-based design of inhibitors of purine nucleoside phosphorylase. 4. A study of phosphate mimics.
April 1994, Journal of medicinal chemistry,
Copied contents to your clipboard!